Economics of stockpiling for an influenza pandemic

The Lancet Infectious Diseases

Volumn 9, Issue 8, 2009, Pages 459-460

  Dhankhar, Praveen ^a   Dasbach, Erik J ^a   Elbasha, Elamin H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PNEUMOCOCCUS VACCINE;

BACTERIAL INFECTION; COST EFFECTIVENESS ANALYSIS; DRUG STORAGE; FINANCIAL MANAGEMENT; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH ECONOMICS; HEALTH SERVICE; INFLUENZA; LETTER; PANDEMIC; PNEUMOCOCCAL INFECTION; PRIORITY JOURNAL; PROBABILITY; QUANTITATIVE ANALYSIS; SHELF LIFE; VACCINATION;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DISEASE OUTBREAKS; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MODELS, ECONOMIC; TIME FACTORS;

EID: 67650538144     PISSN: 14733099     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1473-3099(09)70183-5     Document Type: Letter

References (13)

1. Morens D.M., Taubenberger J.K., and Fauci A.S. Predominant role of bacterial pneumonia as a cause of death in pandemic influenza: implications for pandemic influenza preparedness. J Infect Dis 198 (2008) 962-970
2. Brundage J.F. Interactions between influenza and bacterial respiratory pathogens: implications for pandemic preparedness. Lancet Infect Dis 6 (2006) 303-312
3. Brundage J.F., and Shanks G.D. Deaths from bacterial pneumonia during 1918-19 influenza pandemic. Emerg Infect Dis 14 (2008) 1193-1199
4. Merck. Pneumovax 23 prescribing information. https://www.merckvaccines.com/pneumProductPage_frmst.html (accessed June 18, 2009).
5. Moberley S.A., Holden J., Tatham D.P., and Andrews R.M. Vaccines for preventing pneumococcal infection in adults. Cochrane Database Syst Rev 1 (2008) CD000422.
6. McCullers J.A. Planning for an influenza pandemic: thinking beyond the virus. J Infect Dis 198 (2008) 945-947
7. Meltzer M.I. Health economics and prioritising health care. Lancet 372 (2008) 612-613
8. Meltzer M.I. Introduction to health economics for physicians. Lancet 358 (2001) 993-998
9. Messonnier M.L., Zhou F., and Moore M.R. Cost-effectiveness of using 23-valent pneumococcal polysaccharide vaccine to prevent pneumococcal pneumonia in target population groups during an influenza pandemic in the United States. Presentations to Advisory Committee on Immunization Practices, Atlanta, Feb 25, 2009. http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-feb09/07-2-pneu.pdf (accessed June 18, 2009).
10. Lee V.J., Phua K.H., Chenm M.I., et al. Economics of neuraminidase inhibitor stockpiling for pandemic influenza. Emerg Infect Dis 12 (2006) 95-102
11. Siddiqui M.R., and Edmunds W.J. Cost-effectiveness of antiviral stockpiling and near-patient testing for potential influenza pandemic, Singapore. Emerg Infect Dis 14 (2008) 267-274
12. Basili M., and Franzini M. Understanding the risk of an avian flu pandemic: rational waiting or precautionary failure?. Risk Anal 26 (2006) 617-630
13. Weniger B.G., Chen R.T., Jacobson S.H., et al. Addressing the challenges to immunization practice with an economic algorithm for vaccine selection. Vaccine 16 (1998) 1885-1897